Stock events for EyePoint Plc (EYPT)
EyePoint Pharmaceuticals' stock has experienced significant movements, including a 180.06% increase over the last 12 months and 29.88% in the past month, but a year-to-date return of -3.89%. Q4 and full-year 2025 financial results showed a decrease in revenue and a widened net loss due to increased investment in DURAVYU trials. DURAVYU's Phase 3 trials for wet AMD are on track, and Phase 3 trials for DME have commenced. A public offering in October 2025 boosted cash reserves, expected to fund operations into Q4 2027. A U.S. patent for the DURAVYU insert formulation was issued, extending coverage into 2043.
Demand Seasonality affecting EyePoint Plc’s stock price
There is no information available regarding demand seasonality for EyePoint Pharmaceuticals' products and services.
Overview of EyePoint Plc’s business
EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing ophthalmic products for eye diseases, utilizing its Durasert E and Verisome technology platforms. Key products include ILUVIEN, YUTIQ, DEXYCU, DURAVYU, and EYP-2301.
EYPT’s Geographic footprint
EyePoint Pharmaceuticals has operations in the U.S., China, and the UK, with the majority of revenue from the United States. The company is headquartered in Watertown, Massachusetts, and has a manufacturing facility in Northbridge, Massachusetts.
EYPT Corporate Image Assessment
While direct information is limited, EyePoint Pharmaceuticals' brand reputation benefits from the advancement of DURAVYU through Phase 3 trials, positive safety data, and a strong cash runway. Increased R&D investment and the widening net loss reflect a strategic focus on pipeline development, not necessarily impacting the brand's reputation for product quality or ethical conduct.
Ownership
EyePoint Pharmaceuticals' stock is held by institutional, insider, and retail investors. Institutional investors own approximately 25.89% to 37.11% of the company's stock, insiders own 10.89%, and public companies and individual investors own 11.22% to 51.99%. Major institutional owners include Cormorant Asset Management, LP, SUVRETTA CAPITAL MANAGEMENT, LLC, and BlackRock, Inc. Ew Healthcare Partners LP and Pfizer Inc are significant insider owners.
